Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.

Paola Portillo-SanchezFernando BrilRomina LomonacoDiana BarbBeverly OrsakJan Marie BruderKenneth Cusi

Published in: Journal of diabetes (2018)

Treatment of patients with prediabetes or T2DM with pioglitazone for up to 3 years was associated with decreased BMD at the level of the lumbar spine. This reduction in BMD at the lumbar spine at 18 months versus placebo suggests an early deleterious effect of pioglitazone on bone metabolism.

Keyphrases

bone mineral density
postmenopausal women
clinical trial
body composition
double blind
phase iii
open label
randomized controlled trial
combination therapy